NCT01337089 2023-04-12
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
Clinical Trials
21 trialsNCT01361607 2023-04-12
SPRAY III
Jazz Pharmaceuticals
Phase 3 Completed
NCT01424566 2023-04-12
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 3 Completed
NCT02609828 2023-02-16
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Pfizer
Phase 3 Completed
NCT04808531 2022-04-12
NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
Medlab Clinical
Phase 3 Unknown
NCT04572776 2021-11-09
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 3 Withdrawn
NCT01964378 2021-07-15
CORAL
Tris Pharma, Inc.
Phase 3 Terminated
NCT03031938 2021-06-25
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Pfizer
Phase 3 Completed
NCT00684632 2020-08-28
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00472303 2019-11-04
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
Grünenthal GmbH
Phase 3 Completed
NCT03967327 2019-06-11
A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Unknown
NCT01675622 2018-05-21
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01326689 2017-03-08
2246-004
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT01384292 2015-06-01
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Phase 3 Terminated
NCT00803283 2013-08-12
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
Johnson & Johnson Taiwan Ltd
Phase 3 Terminated
NCT01309386 2013-03-13
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT00126789 2012-06-05
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
ZARS Pharma Inc.
Phase 3 Terminated
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00410540 2010-04-27
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
Alza Corporation, DE, USA
Phase 3 Completed
NCT00410943 2010-04-27
Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain
Alza Corporation, DE, USA
Phase 3 Completed
NCT00911261 2010-02-15
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
Endo Pharmaceuticals
Phase 3 Completed